Thus, the ex vivo selection or enrichment of CXCR3+ CD8+ T cells appears as a promising strategy for optimizing the efficacy of therapeutic concepts, which are based on the adoptive transfer of tumor-targeting T cells in the clinical context of CRC [25]. Here, CXCR3 is linked to neoplasm.